New CAR T-Cell therapy KITE-753 takes on standard treatment in lymphoma showdown

NCT ID NCT07479797

Recruiting now Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated Jun 11, 2026 · Updated 12 times

Summary

This phase 3 study tests whether a new treatment called KITE-753 works better than the current CAR T-cell therapy, axicabtagene ciloleucel, for adults with large B-cell lymphoma that has come back or not responded after initial treatment. About 550 participants will be randomly assigned to receive one of the two therapies. The main goal is to see which treatment leads to more complete remissions at 6 months and longer event-free survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Stanford University
RECRUITING

Stanford, California, 94305, United States

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)